Project Grant R01HL171042
Award Date
9/1/24
Completion Date
7/31/29
Dollars Obligated
$686K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $764,817 to the University of North Carolina at Chapel Hill to conduct research on the mechanisms of coagulopathy and bleeding in acute promyelocytic leukemia (APL). The study aims to determine the individual contributions of the podoplanin-CLEC-2 pathway, the S100/Annexin A2/tissue plasminogen activator and the urokinase-type plasminogen...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), aims to characterize the role of Factor XII (FXII) in the thrombo-inflammatory complications of sickle cell disease (SCD). The $1,449,454 award to the University of North Carolina at Chapel Hill (UNC-CH) will fund research to: 1) identify disease-specific triggers of FXII activation, 2) characterize FXII effects on neutrophil...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $767,077 to the University of North Carolina at Chapel Hill to validate and extend a platform technology for the delivery of protein-based drugs, with a focus on thrombolytic enzymes. The research aims to develop a biocompatible drug delivery system that can leverage the circulatory system as a natural drug depot, release the...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $829,103 to The Trustees of Columbia University in the City of New York to conduct research on functional coagulation and hemostasis after intracerebral hemorrhage (ICH). The goal is to perform a multimodal assessment of coagulation in ICH patients using traditional clinical assays, contemporary whole blood viscoelastic hemostatic assays,...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $151,523 to The Medical College of Wisconsin, Inc. to investigate the role of fibrinogen in regulating inflammation and thrombus resolution in acute and chronic venous thrombosis. The research aims to develop a novel RNA therapy using lipid nanoparticles to selectively reduce circulating fibrinogen levels and elucidate its impact on thromboinflammatory processes....
This federal Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $601,677 to the University of Massachusetts to conduct multi-scale research on the mechanisms underlying a rare but dangerous immunothrombotic side effect, known as vaccine-induced immune thrombotic thrombocytopenia (VITT), associated with adenoviral-vectored vaccines. The research aims to elucidate the molecular and biochemical triggers of VITT...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $723,084 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Regents of the University of Colorado, doing business as the University of Colorado-Denver. The objective of this 4-year grant is to determine the contribution of the PAR1/IL-17 signaling axis to the development of abnormal cellular phenotypes in chronic thrombus, and the initiation and progression of chronic thromboembolic pulmonary hypertension...
This $674,338 Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the genetic architecture regulating tissue factor (TF) expression and its impact on human bleeding and thrombotic risk. The project aims to: 1) Evaluate new transcriptional activators and repressors of the F3 promoter that controls TF expression across human tissues, and identify rare human genetic...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $549,665 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to the University of Maryland, Baltimore to conduct research on "Modulating the Resolution of Angiogenesis and Normalization of the Vasculature for Therapeutic Benefit." The goal is to advance the understanding of the fundamental processes that regulate the resolution of angiogenesis, in order to develop more effective therapeutic approaches for...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $1,371,242 to The University of Texas Rio Grande Valley to conduct research on identifying genetic and environmental factors underlying the high incidence of factor VIII inhibitors in hemophilia A patients of Mexican ancestry. The 4-year project aims to: 1) enroll and characterize a cohort of 200 severe hemophilia A patients, 2) elucidate the genetic basis of...